• Purity

  >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie? Blue Staining.

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its binding ability in a functional ELISA. When Recombinant Human LILRB1/CD85j/ILT2 is coated at 2 μg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # ) binds with a typical ED    ₅₀ of 75-450 ng/mL.

• Source

  Human embryonic kidney cell, HEK293-derived

  Human LILRB1 (Gly24-His458) Accession # Q8NHL6	HHHHHH
  N-terminus	C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  Gly24

• Structure / Form

  Monomer

• Predicted Molecular Mass

  48 kDa

• SDS-PAGE

  65-82 kDa, reducing conditions

Background: LILRB1/CD85j/ILT2

LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family (1). Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs (2). Alternative splicing generates an additional isoform that lacks the transmembrane and cytoplasmic regions (3). LILRB1 is expressed on the surface of B cells and monocytes, as well as subsets of NK cells, memory/effector CD8  ⁺ T cells, gamma δ T cells, and monocyte-derived dendritic cells (3-7). LILRB1 binds to MHC-I as well as non-classical MHC-I molecules (  e.g. HLA-F, HLA-G, and HLA-B27) and the MHC-I mimetic UL18 encoded by cytomegalovirus (3, 5, 8-10). R&D Systems  
in-house testing indicates that LILRB1 also binds to Angiopoietin-like 7. Ligation of LILRB1 inhibits the antigen induced proliferation and activation of CD8  ⁺ T cells, CD4  ⁺ T cells, NK cells, and gamma δ T cells (3, 4, 11-13). On dendritic cells, ligation inhibits the production of IL-10, IL-12p70, and TGF-beta and protects from Fas-mediated apoptosis (7).

• References:

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.

2. Samaridis, J. and M. Colonna (1997) Eur. J. Immunol. 27:660.

3. Colonna, M. et al. (1997) J. Exp. Med. 186:1809.

4. Harly, C. et al. (2011) Blood 117:2864.

5. Cosman, D. et al. (1997) Immunity 7:273.

6. Young, N.T. et al. (2001) J. Immunol. 166:3933.

7. Young, N.T. et al. (2008) Blood 111:3090.

8. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.

9. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:8856.

10. Allen, R.L. et al. (2001) J. Immunol. 167:5543.

11. Ince, M.N. et al. (2004) Immunology 112:531.

12. Saverino, D. et al. (2000) J. Immunol. 165:3742.

13. Saverino, D. et al. (2002) J. Immunol. 168:207.

• Long Name:

  Leukocyte Immunoglobulin-like Receptor, Subfamily A (with TM domain), Member 1

• Entrez Gene IDs:

  10859 (Human)

• Alternate Names:

  CD85 antigen-like family member J; CD85j antigen; CD85j; Ig-like transcript 2; ILT2; ILT-2; ILT2FLJ37515; Immunoglobulin-like transcript 2; leukocyte Ig-like receptor-1; Leukocyte immunoglobulin-like receptor 1; leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform; leukocyte immunoglobulin-like receptor subfamily B member 1; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LILRB1; LIR1; LIR1LIR-1MIR-7CD85MIR7CD85 antigen; member 1; MIR7; Monocyte/macrophage immunoglobulin-like receptor 7